EHA 2019: Ixazomib did not have an adverse impact on quality of life in newly diagnosed multiple myeloma

Fredrik Schjesvold | EHA 2019 | KESÄKUU 18, 2019

Asiantuntija: Fredrik Schjesvold

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomibimproved PFS, and is the first study to evaluate the impact ofmaintenance therapyon quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalkFredrik Schjesvoldpresent the data from the study showing, that active treatment with ixazomibdid not have an adverse impact on HRQoL.